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Histology-Specific MicroRNA Alterations in
Melanoma
Laura Poliseno1, Adele Haimovic1, Miguel F. Segura2, Douglas Hanniford2, Paul J. Christos3,
Farbod Darvishian2,4, Jinhua Wang5,6, Richard L. Shapiro4,7, Anna C. Pavlick4,8, Russell S. Berman4,7,
Eva Hernando2,4, Jiri Zavadil2,6 and Iman Osman1,4,8
We examined the microRNA signature that distinguishes the most common melanoma histological subtypes,
superficial spreading melanoma (SSM) and nodular melanoma (NM). We also investigated the mechanisms
underlying the differential expression of histology-specific microRNAs. MicroRNA array performed on a training
cohort of 82 primary melanoma tumors (26 SSM, 56 NM), and nine congenital nevi (CN) revealed 134 microRNAs
differentially expressed between SSM and NM (Po0.05). Out of 134 microRNAs, 126 remained significant
after controlling for thickness and 31 were expressed at a lower level in SSM compared with both NM and CN.
For seven microRNAs (let-7g, miR-15a, miR-16, miR-138, miR-181a, miR-191, and miR-933), the downregulation
was associated with selective genomic loss in SSM cell lines and primary tumors, but not in NM cell lines and
primary tumors. The lower expression level of six out of seven microRNAs in SSM compared with NM was
confirmed by real-time PCR on a subset of cases in the training cohort and validated in an independent cohort
of 97 melanoma cases (38 SSM, 59 NM). Our data support a molecular classification in which SSM and NM are
two molecularly distinct phenotypes. Therapeutic strategies that take into account subtype-specific alterations
might improve the outcome of melanoma patients.
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INTRODUCTION
The most common histological subtypes of melanoma are
superficial spreading melanoma (SSM, 70% of diagnosed
cases) and nodular melanoma (NM, 20% of diagnosed cases)
(Duncan, 2009). SSM (also known as radial growth phase
(RGP) melanoma) is characterized by a flat appearance and a
slow and horizontal growth. In contrast, NM is usually thicker
than SSM and is characterized by fast growth (Liu et al.,
2006). NM tends to move vertically and penetrate into the
dermis and is therefore referred to as vertical growth phase
(VGP) melanoma.
Currently, melanoma is perceived as a stepwise process in
which normal melanocytes in the basal layer of the epidermis
acquire genetic mutations that allow linear progression from
RGP melanoma to VGP melanoma, and eventually metastatic
melanoma (Kwong et al., 2007). However, clinicopatho-
logical data reported by our group and others suggest that
SSM and NM might not always be two sequential phases of
the same disease (Poetsch et al., 2003; Liu et al., 2007;
Segura et al., 2008; Warycha et al., 2008; Zalaudek et al.,
2008a, 2008b; Baumert et al., 2009; Geller et al., 2009; Rose
et al., 2011).
Here, we use microRNA array profiling and validation to
define SSM- and NM-specific microRNA alterations. Micro-
RNAs are short single-stranded RNA molecules that act as
posttranscriptional regulators of gene expression (Djuranovic
et al., 2011). MicroRNAs were chosen to identify the
differences between SSM and NM because they are accurate
markers of cell identity, and their profile can unambiguously
distinguish between different cell types (Kosik, 2010).
Changes in the expression level of even a single microRNA
can shift the expression profile of the cell, cause the activa-
tion or repression of signaling pathways, and have profound
pathological consequences (Lim et al., 2005; Neveu et al.,
2010).
Our data reveal microRNA alterations that cannot be
explained by NM being thicker than SSM or by the linear
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progression model of melanoma. We therefore propose a
classification in which SSM and NM are molecularly distinct
phenotypes.
RESULTS
134 MicroRNAs are differentially expressed between SSM
and NM
Total RNA extracted from 82 melanoma specimens (26 SSM
and 56 NM, training cohort, Table 1) and 9 congenital nevi
(CN) was analyzed using miRCURY LNA array (Exiqon,
Vedbaek, Denmark) platform. According to both T-test and
SAM analyses, SSM samples formed one cluster, whereas NM
samples showed higher heterogeneity, with some of them
clustered together with the SSM samples and others
completely separated (Figure 1). In all, 160 (T-test) and
165 (SAM) microRNAs showed differential expression
between SSM and NM. A total of 134 microRNAs over-
lapped between the two analyses, of which 98 are canonical
microRNAs and 36 are miRPlus microRNAs. Out of the 134
microRNAs, 75 showed lower expression in SSM compared
with NM, whereas the remaining 59 showed higher
expression in SSM than in NM (Supplementary Table S1
online). The 98 canonical microRNAs were analyzed
using the Ingenuity Software (Redwood city, CA) for
pathway analysis. Among the 51 microRNAs that are
currently characterized enough for functional evaluation,
the majority (39, 76%) are already known to have a role in
human cancer (Supplementary Figure S1 online) and some
of them have specifically been shown to have a role in
melanoma (Felicetti et al., 2008; Gaziel-Sovran et al., 2011).
To examine whether the differences in the microRNA
expression levels between SSM and NM are due to
differences in thickness, the 134 microRNAs differentially
expressed between SSM and NM were reanalyzed by
dividing the 82 samples into two groups according to their
thickness (p2mm thick versus 42mm thick). The vast
majority (126/134, 94%) of the microRNAs were differ-
entially expressed between the two thickness groups
(T-test, Po0.05). These data indicate that their expression
level changes along with the increasing invasion of the
tumor. Nevertheless, SSM and NM samples of comparable
thickness tended to cluster together, suggesting that
thickness cannot account for the differences between
SSM and NM.
The differential expression level of 52 microRNAs cannot be
explained by the linear progression model
To understand the relationship between microRNA altera-
tions and melanoma progression, CN were used for compa-
rison. According to the difference in expression level
between SSM and NM, CN and SSM, and CN and NM, the
microRNAs could be categorized into two groups. The larger
group is composed of 52 microRNAs whose level is altered in
SSM, but (closer to) normal in NM or even showing opposite
alterations in the 2 subtypes, being downregulated in one and
upregulated in the other. This differential expression pattern
is in favor of a non-linear progression model. A smaller
group, composed of 17 microRNAs whose levels progres-
sively increase or decrease in CN-SSM-NM, is consistent
with the linear progression model.
The 52 microRNAs that support the nonlinear progression
model are listed in Supplementary Figure S2 online and
Supplementary Table S2 online. We chose to further study
the subset that is downregulated in SSM compared with both
CN and NM (Figure 2). This category, composed of 31
microRNAs, is the largest.
Table 1. Patient characteristics
Training cohort
(N=82)
Validation cohort
(N=97)
Gender, N (%)
Male 49 (59.8) 64 (66.0)
Female 33 (40.2) 33 (34.0)
Age at diagnosis (years)
Mean±SD 58.9±14.4 63.8±16.5
Histological type, N (%)
SSM 26 (31.7) 38 (39.2)
NM 56 (68.2) 59 (60.8)
Thickness (mm), N (%)
p2 32 (39.0) 30 (30.9)
42 50 (61.0) 67 (69.1)
Ulceration, N (%)
Present 42 (51.2) 51 (52.6)
Absent 40 (48.8) 46 (47.4)
Mitoses per mm2, N (%)
0 5 (6.1) 8 (8.2)
X1 75 (91.5) 89 (91.8)
Unknown 2 (2.4) 0 (0.0)
Stage, N (%)
Stage I 19 (23.2) 18 (18.5)
Stage II 44 (53.6) 39 (40.2)
Stage III 19 (23.2) 38 (39.2)
Stage IV 0 (0.0) 2 (2.1)
LN status, N (%)
Positive 16 (19.5) 33 (34.0)
Negative 66 (80.5) 64 (66.0)
Abbreviations: LN, lymph node; NM, nodular melanoma; SSM, superficial
spreading melanoma.
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Prioritized microRNA loci show deletions in SSM cell lines
but not in NM cell lines
To determine whether the downregulation of the prioritized
microRNAs is due to selective genomic loss in SSM, the
corresponding genomic loci were analyzed by real-time
PCR in 10 melanoma cell lines. In all, 13 loci (48%, in gray in
Figure 3) showed deletion in at least one RGP/SSM-like cell
line and no deletion in VGP/NM-like cell lines. miR-491
locuswas considered as part of this group because although it
is partially deleted in WM983A VGP/NM-like cell line, it
is also the only one that shows complete deletion in one
RGP/SSM-like cell line (WM1552c). Among the remaining
loci, six did not show any deletion across the 10 cell lines,
whereas eight showed deletions in both the RGP/SSM-like
and the VGP/NM-like cell lines. The 13 loci pointing toward
selective genomic deletion in SSM were characterized
further, as described below.
The analysis of the genomic loci corresponding to prioritized
microRNAs confirms the SSM-specific deletion in melanoma
specimens
The selective genomic loss of let-7g, miR-15aB16-1, miR-
17B92, miR-29b-2B29c, miR-30a, miR-30c-2, miR-138-1,
miR-138-2, miR-181a-2B181b-2, miR-191B425, miR-491,
miR-933, and miRPlus-F1147 loci in SSM was confirmed on
genomic DNA extracted from 9 SSM and 16 NM specimens,
whereas 13 CNs were used as control. In all, 2 out of the 9
SSM and 12 out of the 16 NM samples were originally present
in the training cohort. The additional ones included were
chosen so that the overall clinicopathological characteristics
of the 25 samples used for genomic DNA extraction were not
different from those used for RNA extraction and microRNA
array (P40.05, data not shown). The results of this
analysis are reported in Figure 4 and Supplementary
Figure S3 online. Six loci (let-7g, miR-15aB16-1, miR-138-2,
T-test, P<0.05 SAM, FDR<10%
NM/SSM
–1.5 1.50
Fold change (log2)
Figure 1. Expression profiling reveals 134 microRNAs that are differentially expressed between superficial spreading melanoma (SSM) and nodular
melanoma (NM). Heat map representing the differentially expressed microRNAs according to T-test, Po0.05 (left), and SAM, false discovery rate (FDR)o10%
(right). T-test and SAM identify 160 and 165 differentially expressed microRNAs, respectively. In all, 134 microRNAs overlap between the two analyses.
For 126 of the 134 microRNAs, the differences between SSM and NM could not be accounted for by thickness.
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miR-181a-2B181b-2, miR-191B425, and miR-933; Figure 4)
showed lower copy number in SSM versus NM (Po0.05),
supporting the results obtained by microRNA array and by
genomic PCR on melanoma cell lines. miR-138-2, miR-
191B425, and miR-933 loci showed lower copy number
compared with CN as well.
miR-15aB16-1 is a bicistronic cluster expressing miR-15a
and miR-16, which both belong to the subset under study
(Figure 2). The miR-181a-2B181b-2 bicistronic cluster
expresses miR-181a and miR-181b. Both microRNAs belong
to the subset under study (Figure 2), but the differences in
expression level of miR-181b across CN, SSM, and NM do
not reach the required statistical significance (Supplementary
Table S2 online). The bicistronic miR-191B425 cluster
expresses miR-191 and miR-425. Contrary to miR-191,
miR-425 is not detectable in SSM nor in NM.
Validation of microarray data by real-time PCR
The seven microRNAs that we found to be downregulated
(Figure 2) and deleted (Figures 3 and 4) in SSM compared
with NM (let-7g, miR-15a, miR-16, miR-138, miR-181a, miR-
191, and miR-933) were further analyzed. The expression
levels of these microRNAs in CN, SSM, and NM, as obtained
from the microRNA array performed on the training cohort,
are reported in Supplementary Figure S4a online. The
differences in expression reached statistical significance in
at least one of the following tests: T-test, Mann–Whitney test,
or Wilcoxon’s rank-sum test.
To confirm the data obtained with the microarray platform
using a different technique, we quantified the levels of
mature let-7g, miR-15a, miR-16, miR-138, miR-181a, and
miR-191 by real-time PCR on seven SSM and seven NM
samples belonging to the training cohort. As reported in
Supplementary Figure S5 online, real-time PCR confirmed
that all the tested microRNAs are expressed at a higher level
in NM than in SSM, validating the data obtained by
microRNA array.
The analysis of an independent validation cohort confirms
the lower expression of the selected microRNAs in SSM
compared with NM
The expression level of the selected microRNAs was checked
by miRCURY LNA array (Exiqon) on 97 additional melanoma
primary tumors (38 SSM and 59 NM, validation cohort,
Table 1). The validation cohort showed that all the micro-
RNAs of interest, except for miR-933, are expressed at a
lower level in SSM compared with NM (Figure 5 and
Supplementary Figure S4b online), confirming the results
obtained in the training cohort.
The validation cohort was also used to explore the
prognostic value of let-7g, miR-15a, miR-16, miR-138, miR-
181a, and miR-191. The expression level of these microRNAs
in the samples of patients who did or did not recur over
a median follow-up period of 33 months (5–150 months
range) was compared. The SSM samples show a general
trend toward lower expression level in the patients who
recurred (let-7g, P–value¼0.067; miR-15a, P-value¼0.071).
The difference was statistically significant for miR-191
(P-value¼ 0.029). Interestingly, this trend is not evident in
NM samples and is actually reversed in the case of miR-138
(P-value¼ 0.031).
The identified microRNAs that are selectively downregulated
and deleted in SSM share overlapping predicted targets
The six microRNAs that we found to be downregulated
in both the training and in the validation cohort (let-7g, miR-
15a, miR-16, miR-138, miR-181a, and miR-191) were further
analyzed. TargetScan prediction algorithm (http://www.
targetscan.org/) was used to obtain the predicted targets for
each of them. As these microRNAs are co-downregulated
and possibly co-deleted in SSM, we decided to focus on
their common targets. The predicted targets that are shared
by each microRNA with the other five are indicated in
Supplementary Figure S6a online and listed in Supplemen-
tary Table S3 online. On average, each microRNA shares
22.4% of its predicted targets with the others. As reported
in Supplementary Figure S6b online, 13 targets are
shared by three of the microRNAs. Although their role in
melanoma has not been studied yet, some (ADAMTS5,
EN2, MSI1, TEAD1) are known to have an oncogenic role
in other cancer types.
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Figure 2. MicroRNAs that are specifically downregulated in superficial
spreading melanoma (SSM) compared with both congenital nevi (CN) and
nodular melanoma (NM). In all, 31 microRNAs belong to this category
according to T-test and/or Mann–Whitney test (Po0.05), and they are all
listed on the left. On the right, miR-15a is shown as an example in the upper
panel, whereas a cartoon summarizing the relationship among CN, SSM, and
NM is reported in the lower panel. The black arrow on the side indicates
increasing expression levels. *Po0.05.
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DISCUSSION
Investigations in almost every solid malignancy suggest that a
thorough understanding of the molecular defects of tumor
histological subtypes is critical for the development of effec-
tive targeted therapy. The identification of distinct mole-
cular alterations characterizing acral lentiginous melanoma,
mucosal melanoma, and uveal melanoma has prompted the
initiation of phase II trials evaluating the efficacy of the c-KIT
inhibitor Imatinib as part of a subtype-specific melanoma
treatment strategy (Eton et al., 2004; Wyman et al., 2006).
Acral lentiginous melanoma, mucosal melanoma, and uveal
melanoma, however, comprises only a small percentage of
melanomas diagnosed in the United States (o5%). On the
contrary, superficial spreading and nodular melanoma histo-
logical subtypes, which represent 70 and 20% of newly
diagnosed cases, respectively, are not currently taken into
account in decision making, and their molecular classification
has not been defined yet.
Although previous studies have mainly focused on the
identification of microRNAs associated with melanoma
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Figure 3. Thirteen microRNA loci are deleted in radial growth phase (RGP)/superficial spreading melanoma (SSM)–like cell lines and not in vertical
growth phase (VGP)/nodular melanoma (NM)–like cell lines. The genomic loci corresponding to the 31 microRNAs listed in Figure 2 were analyzed by
real-time PCR in 10 primary melanoma cell lines. The second column indicates whether each microRNA was identified using T-test (T) or Mann–Whitney
test (MW). The cluster to which each microRNA belongs and its genomic location are reported in the third and fourth column, respectively. RGP/SSM-like cell
lines are in blue and VGP/NM-like cell lines are in red. The 13 loci that were subjected to further analyses are highlighted in gray.
1864 Journal of Investigative Dermatology (2012), Volume 132
L Poliseno et al.
SSM and NM Are Molecularly Distinct Melanoma Subtypes
progression (Mueller et al., 2009; Caramuta et al., 2010;
Philippidou et al., 2010), in this study we have identified the
134-microRNA signature that distinguishes SSM and NM
primary melanoma subtypes. The subset of microRNAs that
we found selectively downregulated in SSM compared with
both nevi and NM was further studied in order to formally
prove that SSM and NM are two different biological entities
that do not always arise one from the other. By using an initial
screening in ‘‘RGP/SSM-like’’ and ‘‘VGP/NM-like’’ melano-
ma cell lines, and then SSM and NM primary melanoma
specimens, we were in fact able to identify seven microRNAs
whose genomic loci are selectively lost in SSM. We
argue that, although the compensatory amplification of the
remaining allele can in theory take place, it is unlikely that a
genomic locus that is partially lost at a certain point of tumor
progression is regained at later stages. Therefore, we consider
the microRNA loci that we found selectively lost in SSM
as a proof of principle that SSM and NM are not sequential
phases of melanoma progression.
SSM is the most common histopathological subtype of
melanoma and its incidence has risen in the past decades in
spite of increased surveillance and earlier detection (Linos
et al., 2009). Although SSM tends to be less aggressive than
NM, it does have the ability to metastasize and be fatal.
Furthermore, owing to the higher prevalence rate of SSM
compared with NM, SSM accounts for a significant portion of
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Figure 4. Validation of the genomic loss of let-7g, miR-15a, miR-16, miR-138, miR-181a, miR-191, and miR-933 in melanoma specimens. Copy number
of the microRNA loci corresponding to the seven microRNAs in congenital nevi (CN) (black), superficial spreading melanoma (SSM) (blue), and nodular
melanoma (NM) (red) primary tumor specimens. The bicistronic miR-15aB16-1 expresses both miR-15a and miR-16. *Po0.05; **Po0.01; ***Po0.001.
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Figure 5. Expression level of let-7g, miR-15a, miR-16, miR-138, miR-181a, and miR-191 in the melanoma specimens belonging to the validation cohort.
The difference in expression level of the indicated microRNAs between the 38 superficial spreading melanoma (SSM) and the 59 nodular melanoma
(NM) samples belonging to the validation cohort is reported. *Po0.05; **Po0.01.
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melanoma-related deaths (Gimotty et al., 2007; Shaikh et al.,
2011). Therefore, it is of pivotal importance to identify the
alterations that can specifically drive SSM pathogenesis and
that can potentially be exploited to develop tailored
therapeutic approaches.
Our microarray analysis on the 82 primary melanoma
samples composing the training cohort and the 97 primary
melanoma samples composing the validation cohort indi-
cates that let-7g, miR-15a, miR-16, miR-138, miR-181a, and
miR-191 are consistently expressed at lower levels in SSM
than in NM (Figures 2 and 5), possibly because of genomic
deletion (Figures 3 and 4). Several pieces of evidence suggest
that the diminished expression of these six microRNAs in
SSM may contribute to the onset of this melanoma subtype,
as described below.
First, these microRNAs have been shown to have an
oncosuppressive role in other cancers (see Supplementary
Table S4 online for references). In general, they are expressed
at a lower level in tumors compared with non-tumoral
tissues, and oppose tumor progression by decreasing the
abundance of multiple oncogenic targets. Interestingly, some
of these targets, such as WNT3A, are known to have an
oncogenic role in melanoma as well, although their possible
differential contribution to the pathogenesis of SSM and
NM has not been considered before.
The canonical WNT1/WNT3A-b-catenin pathway is
crucial in the early phases of melanoma. b-Catenin causes
the malignant transformation of melanocytes, because it
directly represses p16/CDKN2A transcription and, conse-
quently, provides melanocytes with an escape from senes-
cence (O’Connell and Weeraratna, 2009). The loss of p16 is
known to be a more common event in SSM than in NM, and
the mechanisms reported thus far (genomic deletion, pro-
moter methylation, and mutation) fail to explain all the cases
where the loss occurs (Poetsch et al., 2003). As amplification
or activating mutations in WNT3A have not been detected,
we postulate that the loss of miR-15aBmiR-16-1 locus might
be an SSM-specific mechanism by which WNT3A is
upregulated, WNT signaling increases, and p16 transcription
is blunted, a mechanism that has not been previously repor-
ted. It is also noteworthy that another target of miR-15a/
miR-16, the proto-oncogene c-MYB, is upregulated in SSM
compared with NM according to two previously published
data sets (Jaeger et al., 2007; Scatolini et al., 2010). As c-MYB
has been recently shown to cooperate with the WNT signal-
ing pathway in colorectal cancer tumorigenesis (Ciznadija
et al., 2009), it is tempting to speculate that the downregu-
lation/deletion of miR-15a/16 might result in two, coopera-
tive oncogenic hits.
Second, the oncosuppressive activity of the identified
microRNAs is reinforced by some of the predicted targets that
they share. Multiple microRNAs are known to bind to the
same mRNA and cooperate in its downregulation (Hobert,
2004). As we found that let-7g, miR-15a, miR-16, miR-138,
miR-181a, and miR-191 were co-downregulated and co-
deleted, we looked for those genes that are predicted to be
targeted by at least two of them and hence may be the most
affected from the concomitant decrease in their levels. We
found 13 predicted targets that are shared by three micro-
RNAs (Supplementary Figure S6 online). Interestingly, most of
these targets are expressed at a higher level in SSM than in
NM according to two previously published data sets (Jaeger
et al., 2007; Scatolini et al., 2010) (Supplementary Figure S7
online), a pattern that is consistent with the downregulation/
deletion of the selected microRNAs in SSM compared
with NM.
Two among the predicted overlapping targets, TNRC6B
and CNOT6L, are known to have a role in microRNA-guided
posttranscriptional repression (Baillat and Shiekhattar, 2009;
Piao et al., 2010). CNOT6L is a deadenylase that removes
poly(A) tails from mRNAs destabilized by microRNAs (Baillat
and Shiekhattar, 2009; Piao et al., 2010). These two predicted
targets suggest that the deletion/downregulation of the
identified microRNAs could impact the microRNA network
as a whole.
Many of the remaining predicted genes have a well-
established oncogenic role in other cancer types (see
Supplementary Table S5 online for references), and might
be responsible for the potential oncosuppressive functions of
the microRNAs that we have found deleted/downregulated in
SSM. Indeed, MSI1, which is a cancer stem cell marker, has
been recently shown to be directly targeted by miR-138 (Vo
et al., 2011), validating the prediction obtained using
TargetScan. Furthermore, MSI1 is known to sustain the
cancer stem cell pool by activating the WNT pathway
(Sanchez-Diaz et al., 2008; Wang et al., 2008). Therefore, it
is possible that the concomitant downregulation of miR-15a/
16 and miR-138 could cause the SSM-specific activation of
the WNT signaling by multiple mechanisms.
Third, genomic loss has been previously associated with the
downregulation of the identified microRNAs, supporting our
results. The miR-15aB16-1 locus on 13q14.3 and the let-7g
locus on 3p21.1 are located in minimal deleted regions, as
reported in B-CLL and epithelial cancer, respectively (Calin
et al., 2004). In addition, miR-138-2 locus on 16q13 is deleted
in ovarian cancer and melanoma (Zhang et al., 2006). It is
noteworthy that the analysis of a melanoma SNP array recently
published by our group (Rose et al., 2011) indicates that all the
loci corresponding to the identified microRNAs are not part of
large deletions. Some of them are indeed located close to other
important tumor suppressor genes with a role in melanoma,
such as BRCA1-associated protein 1 on 3p21.1 together with
let-7g, and RAS association domain family member 1 on
3p21.3 together with miR-191B425 (Harbour et al., 2010; Yi
et al., 2011). Nevertheless, the ‘‘focal’’ nature of the deletion of
the identified microRNA loci suggest that they might be
‘‘drivers’’ and not simply ‘‘passengers’’ in SSM pathogenesis
(Akavia et al., 2010).
In conclusion, in this study we have identified down-
regulation and loss in microRNA genes that are specific for
the SSM (but not NM) subtype. We propose that these
alterations may constitute an SSM-specific ‘‘point of entry’’
for the activation of oncogenic and possibly cancer stem
cell–related pathways. Overall, our data lend support to the
incorporation of genetic signature into the histopathologic
classification of melanoma subtypes.
1866 Journal of Investigative Dermatology (2012), Volume 132
L Poliseno et al.
SSM and NM Are Molecularly Distinct Melanoma Subtypes
MATERIALS AND METHODS
Human melanoma tissues
Patients were prospectively enrolled into the Interdisciplinary
Melanoma Cooperative Group (IMCG) database (Wich et al.,
2009) since August 2002. All patients provided written consent at
enrollment and the Internal Review Board of NYU approved the
study. Information about the characteristics of the primary tumors
was collected, including histologic subtype, age at diagnosis, stage,
thickness, ulceration, number of mitoses per mm2, lymph node (LN)
status and recurrence. Tumors designated as NM demonstrate
aggressive vertical growth with large dermal nests and sheets of
cytologically atypical melanocytes. To distinguish NM from SSM
that extends into the dermis, NM cannot have evidence of
melanoma cells in the epidermis extending beyond 3 rete ridges
lateral to the dermal component (Smoller, 2006). The study was
conducted according to Declaration of Helsinki Principles.
Melanoma specimens were sectioned on Leica Membrane Slides
PEN and laser-capture microdissected, using a LMD6000 Leica Laser
Micro-Dissection System (NYU CI Histopathology Core; Buffalo
Grove, IL). Two to ten 10-mm slides were used per specimen. Total
RNA from these samples was extracted using miRNeasy FFPE Tissue
Kit (Qiagen, Hilden, Germany) and quantified using a Nanodrop
Spectrophotometer (Thermo Scientific, Wilmington, DE).
Human melanoma cell lines
Normal melanocytes were obtained from infant foreskin (NHM) and
grown in supplemented melanocyte growth medium (PromoCell,
Heidelberg, Germany).
Primary RGP/SSM-like (WM35, WM1552c, WM1575, WM3211)
and VGP/NM-like (WM98.1, WM278, WM793B, WM853.2,
WM902B, WM983A) melanoma cell lines were purchased from
the Wistar Institute (Philadelphia, PA) and cultured in Mel 2%
medium (Fang et al., 2005). They were not further tested or
authenticated.
MicroRNA array
Following quality control, 300 ng of RNA was labeled with Cy3 and
co-hybridized with a Cy5-labeled reference sample (equal mixture
of all arrayed samples) to miRCURY LNA version 11.0 array platform
(miRBase v. 14.0, Exiqon) on Tecan HS4800 Pro automated
hybridization stations and scanned on Agilent G25605BA Micro-
array Scanners (Santa Clara, CA). Image analyses (ImaGene 8.0
software, Biodiscovery, El Segundo, CA) were performed in order to
quantify the signals of the arrays. Technical quality assessment of the
data was performed based on results from synthetic spike-in control
RNAs. The microRNA array used in this study contains probes for 26
control small RNAs, 79 viral microRNAs, and 1264 human
microRNAs. The sequence of 838 out of the 1264 human
microRNAs (hsa-miR) is available at http://www.mirbase.org/, while
the remaining 426 microRNAs (hsa-miRPlus) are proprietary small
RNAs identified by EXIQON. MicroRNA array results were analyzed
as described in Supplemental Text S1 (online).
Real time PCR on genomic DNA and on mature microRNAs
Real time PCR was performed according to standard procedures,
which are described in detail in Supplemental Text S1 and in
Supplementary Table S6 online.
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